Edgewise Therapeutics (EWTX) PT Raised to $52 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Edgewise Therapeutics sells sevasemten to Servier for up to $2.65 billion
June 1, 2026 8:31 AM EDTEdgewise Therapeutics Inc. (NASDAQ: EWTX) announced it entered into a definitive agreement to sell sevasemten and its muscular dystrophy business to Servier for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments.
Under the agreement, Servier will acquire all rights to sevasemten, including intellectual property, regulatory filings, and clinical data. Edgewise employees primarily supporting... More
Servier to acquire Edgewise muscular dystrophy business for $2.65 billion
June 1, 2026 8:30 AM EDTServier announced an agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc. (NASDAQ: EWTX) for up to $2.65 billion. The transaction includes an upfront payment of $1.55 billion and up to $1.1 billion in regulatory and commercial milestone payments.
The acquisition includes sevasemten, an investigational oral treatment for Becker and... More
